Arkuda Therapeutics secured $64 million in Series B financing. This adds to the $44 million Series A the company achieved in November 2019.

Temps are falling and so is investor cash as BioSpace reviewed which biotech companies are scooping up the dollars.

Engitix Therapeutics raised $54 million in Series A financing. Engitix plans to use the money to boost the company’s drug discovery pipeline in fibrosis and cancer and expand its team, facilities and operations.

Massachusetts-based Kytopen has seen an influx of cash during the past few months. Most recently, the biotech raised a large chunk of money in the company’s Series A funding round, which was announced on Sept. 28.

The IPO train continues to barrel down the tracks as more life sciences companies announced and closed their initial public offerings, bringing millions more to their coffers. 

Doceree Inc., the first global network of physician-only platforms for programmatic marketing, raised a pre-Series A funding for an undisclosed amount led by existing and new investors.

Mayo Clinic launched two new tech venture companies designed to harness artificial intelligence (AI) and medical algorithms and create “software as medical devices” that clinicians can use to improve treatment across different diseases. 

BioSpace presented the NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.

Find out which biopharma companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.

U.K.-based NodThera is building up the company’s war chest to develop therapies for diseases driven by chronic inflammation, securing $55 million in Series B financing.